Indirect comparison of efficacy and safety of chiglitazar and thiazolidinedione in patients with type 2 diabetes: A meta-analysis

BACKGROUND: Chiglitazar is an emerging pan-agonist of all peroxisome proliferator activated receptors (PPAR)-α, δ and γ, and has therapeutic potential for type 2 diabetes (T2D). However, to date, no clinical studies or meta-analyses have compared the efficacy and safety of chiglitazar and traditiona...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Chu, Li, Zong-Lin, Cai, Xiao-Ling, Hu, Sui-Yuan, Lv, Fang, Yang, Wen-Jia, Ji, Li-Nong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642417/
https://www.ncbi.nlm.nih.gov/pubmed/37970134
http://dx.doi.org/10.4239/wjd.v14.i10.1573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642417/
https://www.ncbi.nlm.nih.gov/pubmed/37970134
http://dx.doi.org/10.4239/wjd.v14.i10.1573

Ejemplares similares